This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Sanjivani consolidated quarter revenue up 63%, profit up 153%; results approved
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended 30 September 2026, revenue from operations rose 63.4% to Rs 2,532.64 lakh from Rs 1,549.73 lakh a year earlier, while profit after tax rose 153.1% to Rs 414.71 lakh from Rs 163.85 lakh. EBITDA margin rose from 14.5% to 25.6%. Consolidated half-year revenue was Rs 4,916.56 lakh, profit after tax Rs 663.82 lakh and positive operating cash flow of Rs 128.96 lakh. The board approved the unaudited results.
Strong revenue, profit and margin growth may support the stock, but rising finance costs and borrowings remain risks.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹25.33 Cr | ₹18.50 Cr | +36.9% |
| Operating profit | ₹5.43 Cr | ₹5.03 Cr | +8.0% |
| Profit after tax | ₹4.15 Cr | ₹4.64 Cr | −10.6% |
| EBITDA margin | 25.6% | 28.4% | −2.8 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.